Skip to main content

Drug Metabolism and Transport Under Hypoxia

Buy Article:

$68.00 + tax (Refund Policy)

Tumour progression is characterized by a rapid cell growth accompanied by changes in the microenvironment, largely due to hypoxia. The angiogenic switch involves changes in the expression of genes that play key roles in tumour progression, invasion, metastasis and therapeutic response, contributing to tumour aggressiveness. The effect of hypoxia on the cellular concentrations of drug metabolizing enzymes and transporters is much less understood.

A brief summary of the signaling mechanisms triggered by hypoxia is presented, followed by a review of the known effects of hypoxia on drug metabolism and transport. Most of the studies available have focused on Cytochromes P450 and ATP-binding cassette transporters, while influx transporters of the SLC family have been less investigated.

Given its potential to contribute both to the understanding of the pathogenesis of disease and to the optimization of therapeutics, it is rather surprising that this area of research is still underdeveloped. An increasing number of studies focusing on this subject are bound to provide key information for drug development and optimization of therapeutics.

Keywords: ABC transporters; Cytochromes P450; SLC transporters; hypoxia

Document Type: Research Article

Publication date: 01 November 2013

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content